Oramed Pharmaceuticals Inc. (ORMP)
| Market Cap | 162.23M +73.5% |
| Revenue (ttm) | n/a |
| Net Income | 174.06M |
| EPS | 4.15 |
| Shares Out | 41.60M |
| PE Ratio | 0.94 |
| Forward PE | n/a |
| Dividend | $0.25 (6.39%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 23,989 |
| Open | 3.900 |
| Previous Close | 3.890 |
| Day's Range | 3.890 - 4.000 |
| 52-Week Range | 2.090 - 5.470 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Financial Performance
Financial StatementsNews
Oramed Pharmaceuticals Quarterly report: Q2 2026
Oramed Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 10, 2026.
Oramed Pharmaceuticals Proxy statement: Proxy filing
Oramed Pharmaceuticals filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Oramed Pharmaceuticals Proxy statement: Proxy filing
Oramed Pharmaceuticals filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March ...
Oramed to join Russell 2000 and 3000 indexes
Oramed (ORMP) Pharmaceuticals announced that it is set to join the U.S. small cap Russell 2000 and broad-market Russell 3000 Index at the conclusion of the 2026 Russell indexes semi-annual…
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-mark...
Oramed Pharmaceuticals Quarterly report: Q1 2026
Oramed Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 19, 2026.
Oramed Pharmaceuticals Annual report: Q4 2025
Oramed Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.
Lifeward closes strategic partnership agreement with Oramed
Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a dive...
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Or...
Oramed and Lifeward sign strategic transaction
Oramed (ORMP) and Lifeward (LFWD) signed binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of...
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intend...
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while reta...
Oramed declares cash dividend payment of 25c per share
Oramed’s (ORMP) Board of Directors has approved a cash dividend payment of 25c per share to reward shareholders. The dividend will have an ex-dividend date of January 16, with disbursement…
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed ...
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) ...
Oramed declares dividend distribution of common stock purchase rights
Oramed (ORMP) has unanimously adopted a Rights Agreement dated November 17 by and between the company and its rights agent, and declared a dividend of one common stock purchase right…
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 20...
Oramed Pharmaceuticals Quarterly report: Q3 2025
Oramed Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 13, 2025.
Oramed Pharmaceuticals Earnings release: Q3 2025
Oramed Pharmaceuticals released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partners...
Scilex completes first tranche of Oramed warrant repurchase
Scilex Holding Company (SCLX) repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share from Oramed Pharmaceuticals (ORMP) for $13,000,000. A...
Oramed Pharmaceuticals Quarterly report: Q2 2025
Oramed Pharmaceuticals has published its Q2 2025 quarterly earnings report on August 14, 2025.
Oramed Pharmaceuticals Proxy statement: Proxy filing
Oramed Pharmaceuticals filed a proxy statement on July 16, 2025, providing details for shareholder voting and corporate governance matters.
Oramed Pharmaceuticals Quarterly report: Q1 2025
Oramed Pharmaceuticals has published its Q1 2025 quarterly earnings report on May 15, 2025.